TORL-1-23
context therapuetics,biontech,TORL BioTherapeutics
['ovarian', '$cntx', 'biontech']
torl claudin 6 data did not disappoint. 32% orr across all doses in ph 1 dose escalation in ovarian cancer. 75% orr (n=4) at highest dose (2.4mg/kg) in ovarian cancer. lots more to come from claudin 6 at #asco2023. $cntx, biontech 
CEO at @Context_Tx, $CNTX. BoD Praesidia BioTherapeutics and @CureDuchenne. Philly biotech champion.